Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT03781414 |
| Consolidated Lead Sponsor | Novartis |
| Therapeutic Condition Cohort | Immunology, Rheumatology, and Dermatology |
| Clinical Trial Phase | Phase II |
| Overall Recruitment Status | TERMINATED |
| Registered Enrollment | 129 participants (ACTUAL) |
| Registered Start Date | 2019-10-07 |
| WhyStopped Classification | Unspecified |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| USC Norris Comprehensive Cancer Center and Keck Medicine | Los Angeles, CA | Open Hospital Dossier -> |
| University of Colorado Anschutz Medical Campus | Aurora, CO | Open Hospital Dossier -> |
| Northwestern Memorial and Lurie Cancer Center | Chicago, IL | Open Hospital Dossier -> |
| Henry Ford Hospital | Detroit, MI | Open Hospital Dossier -> |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.
Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.